Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1911 1
1923 1
1939 1
1944 2
1945 2
1946 2
1947 2
1948 1
1950 1
1951 2
1952 1
1953 1
1954 2
1955 1
1956 2
1957 2
1958 1
1960 1
1962 1
1963 3
1964 2
1965 3
1966 1
1967 5
1968 6
1969 1
1970 1
1971 7
1972 7
1973 6
1974 5
1975 3
1976 7
1977 4
1978 3
1979 10
1980 6
1981 13
1982 10
1983 3
1984 8
1985 3
1986 5
1987 15
1988 3
1989 8
1990 7
1991 2
1992 8
1993 7
1994 5
1995 8
1996 11
1997 11
1998 9
1999 11
2000 8
2001 7
2002 8
2003 3
2004 1
2005 4
2006 8
2007 12
2008 5
2009 5
2010 3
2011 3
2012 3
2013 6
2014 6
2015 3
2016 2
2017 6
2018 6
2019 5
2020 12
2021 11
2022 13
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Results by year

Filters applied: . Clear all
Page 1
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Shapira T, Monreal IA, Dion SP, Buchholz DW, Imbiakha B, Olmstead AD, Jager M, Désilets A, Gao G, Martins M, Vandal T, Thompson CAH, Chin A, Rees WD, Steiner T, Nabi IR, Marsault E, Sahler J, Diel DG, Van de Walle GR, August A, Whittaker GR, Boudreault PL, Leduc R, Aguilar HC, Jean F. Shapira T, et al. Among authors: rees wd. Nature. 2022 May;605(7909):340-348. doi: 10.1038/s41586-022-04661-w. Epub 2022 Mar 28. Nature. 2022. PMID: 35344983 Free PMC article.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA. Paller AS, et al. Among authors: rees wc. J Am Acad Dermatol. 2016 Sep;75(3):494-503.e6. doi: 10.1016/j.jaad.2016.05.046. Epub 2016 Jul 11. J Am Acad Dermatol. 2016. PMID: 27417017 Free article. Clinical Trial.
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC; N-MOmentum study investigators. Bennett JL, et al. Among authors: rees wa. EBioMedicine. 2022 Dec;86:104321. doi: 10.1016/j.ebiom.2022.104321. Epub 2022 Nov 10. EBioMedicine. 2022. PMID: 36370634 Free PMC article. Clinical Trial.
Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus.
Karnell JL, Wu Y, Mittereder N, Smith MA, Gunsior M, Yan L, Casey KA, Henault J, Riggs JM, Nicholson SM, Sanjuan MA, Vousden KA, Werth VP, Drappa J, Illei GG, Rees WA, Ratchford JN; VIB7734 Trial Investigators. Karnell JL, et al. Among authors: rees wa. Sci Transl Med. 2021 May 26;13(595):eabf8442. doi: 10.1126/scitranslmed.abf8442. Sci Transl Med. 2021. PMID: 34039741 Clinical Trial.
Scientists' warning on population.
Crist E, Ripple WJ, Ehrlich PR, Rees WE, Wolf C. Crist E, et al. Among authors: rees we. Sci Total Environ. 2022 Nov 1;845:157166. doi: 10.1016/j.scitotenv.2022.157166. Epub 2022 Jul 5. Sci Total Environ. 2022. PMID: 35803428
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Weinshenker BG, Wingerchuk DM, Green AJ, Bennett JL, Kim HJ, Pittock SJ, Fujihara K, Paul F, Cutter G, Marignier R, Aktas O, Hartung HP, She D, Smith M, Rees W, Patterson K, Cimbora D, Katz E, Cree BA. Weinshenker BG, et al. Among authors: rees w. Mult Scler. 2023 Jul;29(8):945-955. doi: 10.1177/13524585231172145. Epub 2023 Jun 6. Mult Scler. 2023. PMID: 37282545 Free PMC article. Clinical Trial.
Designing Expandable-Structure Robots for Human-Robot Interaction.
Hedayati H, Suzuki R, Rees W, Leithinger D, Szafir D. Hedayati H, et al. Among authors: rees w. Front Robot AI. 2022 Apr 11;9:719639. doi: 10.3389/frobt.2022.719639. eCollection 2022. Front Robot AI. 2022. PMID: 35480087 Free PMC article. Review.
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BA; N-MOmentum study investigators. Aktas O, et al. Among authors: rees wa. J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):757-768. doi: 10.1136/jnnp-2022-330412. Epub 2023 May 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 37221052 Free PMC article. Clinical Trial.
384 results